Original Contribution | Published:

Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study

American Journal of Gastroenterology volume 98, pages 26162620 (2003) | Download Citation




Proton pump inhibitors owe their clinical efficacy to their ability to suppress gastric acid production. The objective of this study was to evaluate and compare intragastric pH following standard doses of esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole.


This randomized, open-label, comparative five-way crossover study evaluated the 24-h intragastric pH profile of oral esomeprazole 40 mg, lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, and rabeprazole 20 mg once daily in 34 Helicobacter pylori–negative patients aged 18–60 yr with symptoms of gastroesophageal reflux disease. Patients were randomly assigned to one of five treatment sequences and study drug was taken on 5 consecutive mornings 30 minutes prior to a standardized breakfast. A washout period of at least 10 days separated each treatment phase.


Thirty-four patients provided evaluable data for all five comparators. The mean number of hours of evaluable pH data was ≥23.75 hours. On day 5, intragastric pH was maintained above 4.0 for a mean of 14.0 h with esomeprazole, 12.1 h with rabeprazole, 11.8 h with omeprazole, 11.5 h with lansoprazole, and 10.1 h with pantoprazole (p ≤ 0.001 for differences between esomeprazole and all other comparators). Esomeprazole also provided a significantly higher percentage of patients with an intragastric pH greater than 4.0 for more than 12 h relative to the other proton pump inhibitors (p < 0.05). The frequency of adverse events was similar between treatment groups.


Esomeprazole at the standard dose of 40 mg once daily provided more effective control of gastric acid at steady state than standard doses of lansoprazole, omeprazole, pantoprazole, and rabeprazole in patients with symptoms of gastroesophageal reflux disease.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    , , , et al. The pharmacology of the gastric acid pump: The H+,K+ ATPase. Annu Rev Pharmacol Toxicol 1995;35: 277–305.

  2. 2.

    , , . Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002;47: 954–958.

  3. 3.

    , , , et al. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liver Dis 2000;32: 660–666.

  4. 4.

    , , . Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther 2000;14: 709–714.

  5. 5.

    , , , et al. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997;92: 576–581.

  6. 6.

    , , , et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51: 59–67.

  7. 7.

    , , , et al. Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitors. Gastroenterology 2001;120(5)(Suppl1):A-418 (abstract 2140).

  8. 8.

    , , , et al. Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000;14: 861–867.

  9. 9.

    , , , et al. Esomeprazole 40 mg twice daily maintains intragastric pH > 4 for more than 80% of a 24-hour time period. Am J Gastroenterol 2002;97: S20–S21.

  10. 10.

    , , , et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97: 575–583.

  11. 11.

    , , , et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial. Aliment Pharmacol Ther 2000;14: 1249–1258.

  12. 12.

    , , , et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Am J Gastroenterol 2001;96: 656–665.

  13. 13.

    , , , . Relation between oesophageal acid exposure and healing in patients with severe reflux oesophagitis. Gut 1996;38: 649–654.

  14. 14.

    , , , , . Double-blind comparison of omeprazole (40mg od) versus cimetidine (400mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring. Gut 1990;31: 509–513.

  15. 15.

    , , pH, healing rate and symptom relief in patients with GERD. Yale J Biol Med 1999;72: 181–194.

Download references


The authors would like to acknowledge Christopher Rains, Karen van Hoeven, and Caroline Spencer for their assistance with manuscript preparation.

Author information


  1. Oklahoma Foundation for Digestive Research, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA

    • Philip Miner Jr.
  2. Department of Medicine, Graduate Hospital, Philadelphia, USA

    • Philip O Katz
  3. Division of Biostatistics, AstraZeneca, LP, Wilmington, Delaware, USA

    • Yusong Chen
  4. Division of Clinical Research, AstraZeneca, LP, Wilmington, Delaware, USA

    • Mark Sostek


  1. Search for Philip Miner in:

  2. Search for Philip O Katz in:

  3. Search for Yusong Chen in:

  4. Search for Mark Sostek in:

Corresponding author

Correspondence to Philip Miner Jr..

About this article

Publication history






Further reading